Clinical Development, Drug Development, Licensing and Pharmaceutical Companies

Women in STEM with Kristina Torfgard

Drug Target Review

SEPTEMBER 5, 2024

However, my goal was all the time to work with drug development in the pharma industry, so I moved on and started that journey in 1992 when I took on a role as Clinical Research Manager at AstraHässle, a mid-size Swedish pharma company.

Pharma Companies

Pharma Companies Licensing Licensing Disease

Pfizer launches Phase III trial for Lyme disease vaccine

Drug Discovery World

AUGUST 12, 2022

Pfizer has launched a Phase III clinical trial of a vaccine to protect people against Lyme disease, in collaboration with pharmaceutical company Valneva. . VLA15 is the only Lyme disease vaccine candidate currently in clinical development. Official comments .

Vaccine

Vaccine Disease Trials Pharmaceutical Companies

Europe: Where is the drug discovery innovation?

Drug Discovery World

MAY 6, 2024

In this article, DDW’s Diana Spencer highlights several prominent hotspots that are taking the lead on advancing European drug discovery and development. Europe is traditionally a life sciences powerhouse, with a strong tradition in pharmaceutical discovery. In 2022, the continent held a 22.4%

Drugs

Drugs Science Molecular Biology Clinical Trials

International Women’s Day: Female life science leaders

Drug Discovery World

MARCH 7, 2023

She has over 15 years’ experience in corporate finance and restructurings, mergers and acquisitions, joint ventures and intellectual property licensing. Hu was formerly a consultant at McKinsey & Company where she advised pharmaceutical companies on strategic, operational and organizational issues.

International

International Science Pharmaceuticals DNA

Advancing neurological therapies with Dr Bruce Leuchter

Drug Target Review

FEBRUARY 1, 2024

But commitment to neuroscience drug development is critically important given the significant unmet medical needs and the ways in which patients, caregivers, and families suffer. In other cases, well-established biomarker profiles enable patient enrichment strategies in early-stage clinical development.

Therapies

Therapies Drug Development Disease Clinical Development

Drug candidates with blockbuster potential for CNS diseases

Drug Target Review

SEPTEMBER 19, 2024

Could you give us an overview of IRLAB’s current drug development pipeline? IRL1117 is expected to be ready to move into clinical development at the end of 2024/first half 2025.

Disease

Disease Drugs Treatment Drug Development

Where is the drug discovery expertise happening in the UK?

Drug Discovery World

OCTOBER 16, 2023

From the Beatson Institute for Cancer Research in Glasgow, to Edinburgh Drug Discovery in the University of Edinburgh’s Institute for Genetics and Cancer (IGC). At ELRIG’s Scottish Research and Drug Development Forum meeting, DDW’s Diana Spencer provided a snapshot of drug discovery in Scotland.

Drugs

Drugs Science Therapies Targeted Protein Degradation

CASI Pharmaceuticals Partner, BioInvent, Presents Phase I/IIA Data That Suggests BI-1206 Restores Activity Of Rituximab In Relapsed Non-Hodgkin’s Lymphoma Patients

The Pharma Data

JANUARY 27, 2021

ET ) to discuss the results and next steps in clinical development of BI-1206. The Company’s validated, proprietary F.I.R.S.T The Company’s operations in China are conducted through its wholly-owned subsidiary, CASI Pharmaceuticals ( China ) Co., CET ( 11:30 a.m.

Pharmaceuticals

Pharmaceuticals Clinical Trials Licensing Licensing

Biopharma Money on the Move: December 2 – 8

The Pharma Data

DECEMBER 8, 2020

AbCellera’s AI-powered antibody discovery platform speeds the otherwise lengthy and grueling process by analyzing the database of natural immune systems to find antibodies that can be developed into drugs. Tackle the toughest problems in drug development.” The promise to partners is to “move quickly. Reduce cost.

RNA

RNA Protein Expression Therapies Disease

The rise of digital biomarkers in neuroscience drug development

Drug Discovery World

OCTOBER 10, 2022

Will an expansion in the use of effective digital biomarkers help improve the productivity of drug development in neuroscience? Increasingly, digital biomarkers are becoming more effectively used in the discovery and development of drugs that act in the central nervous system. The solution provided by digital biomarkers.

Drug Development

Drug Development Clinical Trials Drugs Trials

The era of precision neuroscience

Drug Discovery World

MARCH 6, 2024

While this is an oversimplification, often patients who share a specific mutation in their tumour can be treated in a similar fashion as they will share this common mechanistic aetiology for their disease, and this is relatively easy to detect using modern sequencing and clinical genomics tools.

Clinical Trials

Clinical Trials Pharmaceutical Companies Disease Trials

Operation Warp Speed for Rare Diseases: Expected Boom in Drug Development and Approval

Advarra

AUGUST 10, 2023

The Orphan Drug Act creates incentives for developing orphan drugs to treat such diseases. However, recent advancements in the clinical use of recombinant DNA (rDNA) technology creates opportunities for changing this calculation and addressing a great, unmet medical need. What is the FDA Proposing to do?

Drug Development

Drug Development Disease Engineering Therapies

Biopharma Leaders Unite To Stand With Science

The Pharma Data

SEPTEMBER 8, 2020

Together, these nine companies have collectively developed more than 70 novel vaccines that have helped to eradicate some of the world’s most complex and deadly public health threats, underscoring their experience in clinical development and regulatory rigor, as well as their longstanding commitments to patient safety and public health.

Science

Science Vaccine Clinical Trials Pharmaceutical Companies

Biopharma Leaders Unite To Stand With Science

The Pharma Data

SEPTEMBER 8, 2020

Together, these nine companies have collectively developed more than 70 novel vaccines that have helped to eradicate some of the world’s most complex and deadly public health threats, underscoring their experience in clinical development and regulatory rigor, as well as their longstanding commitments to patient safety and public health.

Science

Science Vaccine Clinical Trials Pharmaceutical Companies

BioDAOs are Community-Owned Research Translation Engines, Not Investment DAOs

Molecule Blog

MARCH 17, 2023

The university then licenses the IP to an existing pharmaceutical company or a biotech startup, which takes on Investigational New Drug (IND) enabling studies. Funding typically comes from a mix of government agencies, venture capitalists (VCs), and pharmaceutical companies.

Engineering

Engineering Research Government Clinical Trials

Molecular Partners Announces Collaboration With Novartis to Develop Two DARPin(R) Therapies Designed for Potential Use Against COVID-19

The Pharma Data

OCTOBER 27, 2020

Novartis has been granted an option to in-license global rights of MP0420 and MP0423 – multi-targeted direct-acting antiviral therapeutic candidates demonstrating potential efficacy against COVID-19. Upon option exercise, Novartis would be responsible for all further development and commercialization activities.

Therapies

Therapies Virus Treatment Clinical Trials

Athersys Announces Three Appointments to Board of Directors

The Pharma Data

NOVEMBER 15, 2020

a publicly traded biopharmaceutical company, from 2012 to December 2019, managing its international, legal, quality, intellectual property and compliance functions, after serving in other executive roles at Acorda starting in 2004. drug development initiative from 2012 to February 2019. Before joining Acorda, Ms.

Clinical Trials

Clinical Trials Trials Production International

BioLineRx Announces Final Results from Phase 2a COMBAT/KEYNOTE-202 Triple Combination Study of Motixafortide in Second Line Metastatic Pancreatic Cancer (PDAC)

The Pharma Data

DECEMBER 15, 2020

(NASDAQ/TASE: BLRX) is a late clinical-stage biopharmaceutical company focused on oncology. The Company’s business model is to in-license novel compounds, develop them through clinical stages, and then partner with pharmaceutical companies for further clinical development and/or commercialization.

Clinical Trials

Clinical Trials Trials Treatment Therapies

Drug Discovery Digest

Women in STEM with Kristina Torfgard

Pfizer launches Phase III trial for Lyme disease vaccine

Trending Sources

Europe: Where is the drug discovery innovation?

International Women’s Day: Female life science leaders

Advancing neurological therapies with Dr Bruce Leuchter

Drug candidates with blockbuster potential for CNS diseases

Where is the drug discovery expertise happening in the UK?

CASI Pharmaceuticals Partner, BioInvent, Presents Phase I/IIA Data That Suggests BI-1206 Restores Activity Of Rituximab In Relapsed Non-Hodgkin’s Lymphoma Patients

Biopharma Money on the Move: December 2 – 8

The rise of digital biomarkers in neuroscience drug development

The era of precision neuroscience

Operation Warp Speed for Rare Diseases: Expected Boom in Drug Development and Approval

Biopharma Leaders Unite To Stand With Science

Biopharma Leaders Unite To Stand With Science

BioDAOs are Community-Owned Research Translation Engines, Not Investment DAOs

Molecular Partners Announces Collaboration With Novartis to Develop Two DARPin(R) Therapies Designed for Potential Use Against COVID-19

Athersys Announces Three Appointments to Board of Directors

BioLineRx Announces Final Results from Phase 2a COMBAT/KEYNOTE-202 Triple Combination Study of Motixafortide in Second Line Metastatic Pancreatic Cancer (PDAC)

Stay Connected